Home・Список акций・CytoSorbents Corp

CytoSorbents Corp

Закрыт

СекторЗдравоохранение

0.36

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.35

Макс.

0.36

Ключевые показатели
By Trading Economics
Доход	-4.4M -9.5M
Продажи	769K 9.6M
Прибыль на акцию	-0.07
Рентабельность продаж	-99.107
Сотрудники	129
EBITDA	547K -3.3M

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+108.33% upside

Дивиденды
By Acuity
Следующий отчет о доходах	12 нояб. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-383K 23M
Предыдущая цена открытия	0.36
Предыдущая цена закрытия	0.36

Новостные настроения

By Acuity

50%

135 / 340 Рейтинг в Healthcare

CytoSorbents Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 авг. 2026 г., 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10 авг. 2026 г., 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7 авг. 2026 г., 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6 авг. 2026 г., 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5 авг. 2026 г., 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4 авг. 2026 г., 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3 авг. 2026 г., 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31 июл. 2026 г., 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29 июл. 2026 г., 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28 июл. 2026 г., 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27 июл. 2026 г., 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24 июл. 2026 г., 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22 июл. 2026 г., 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 июл. 2026 г., 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20 июл. 2026 г., 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Сравнение c конкурентами

Изменение цены

CytoSorbents Corp Прогноз

Целевая цена

By TipRanks

108.33% рост

Прогноз на 12 месяцев

Средняя 0.75 USD 108.33%

Максимум 0.75 USD

Минимум 0.75 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для CytoSorbents Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

1 ratings

Покупка

Удержание

Продажа

Основано на мнении 1 аналитиков, присваивавших рейтинги акциям CytoSorbents Corp – Данные за последние 3 месяца.

Настроения

By Acuity

135 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.